Ouro Fino Saúde Animal Participações S.A., together with its subsidiaries, operates in the animal health industry primarily in Brazil.
Ouro Fino Saúde Animal Participações Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||R$27.30|
|52 Week High||R$26.40|
|52 Week Low||R$42.00|
|1 Month Change||-7.52%|
|3 Month Change||-19.71%|
|1 Year Change||-5.21%|
|3 Year Change||3.41%|
|5 Year Change||-26.79%|
|Change since IPO||-1.27%|
Recent News & Updates
Ouro Fino Saúde Animal Participações (BVMF:OFSA3) Has A Pretty Healthy Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
|OFSA3||BR Pharmaceuticals||BR Market|
Return vs Industry: OFSA3 matched the BR Pharmaceuticals industry which returned -4.8% over the past year.
Return vs Market: OFSA3 underperformed the BR Market which returned 0.7% over the past year.
Stable Share Price: OFSA3 is not significantly more volatile than the rest of BR stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: OFSA3's weekly volatility (5%) has been stable over the past year.
About the Company
|1987||n/a||Kleber Cesar Gomes||https://www.ourofinosaudeanimal.com|
Ouro Fino Saúde Animal Participações S.A., together with its subsidiaries, operates in the animal health industry primarily in Brazil. The company operates through Production Animals, Companion Animals, and International Operations segments. It engages in the manufacture and sale of veterinary products, vaccines, and other products comprising anti-inflammatories, antibiotics, anticoccidials, anti-mastitis, ectoparasiticides, endectocides, endoparasiticides, hemoparasiticides, inoculants, therapeutics, and products for cattle, pigs, poultry, sheep, horses, and goats; and veterinary solutions, such as anesthetics, sedatives, anti-inflammatory, antibiotic, antimicrobial, dermatological, ectoparasiticide, endoparasiticide, dermocosmetic, and otological products for dogs and cats.
Ouro Fino Saúde Animal Participações Fundamentals Summary
|OFSA3 fundamental statistics|
Is OFSA3 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|OFSA3 income statement (TTM)|
|Cost of Revenue||R$414.07m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Nov 11, 2021
|Earnings per share (EPS)||2.20|
|Net Profit Margin||14.03%|
How did OFSA3 perform over the long term?See historical performance and comparison
Is Ouro Fino Saúde Animal Participações undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: OFSA3 (R$27.3) is trading above our estimate of fair value (R$18.94)
Significantly Below Fair Value: OFSA3 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: OFSA3 is good value based on its PE Ratio (12.4x) compared to the Global Pharmaceuticals industry average (23.1x).
PE vs Market: OFSA3 is poor value based on its PE Ratio (12.4x) compared to the BR market (11.5x).
Price to Earnings Growth Ratio
PEG Ratio: OFSA3's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: OFSA3's PB Ratio (2.4x) is in line with the XS Pharmaceuticals industry average.
How is Ouro Fino Saúde Animal Participações forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OFSA3's earnings are forecast to decline over the next 3 years (-0.3% per year).
Earnings vs Market: OFSA3's earnings are forecast to decline over the next 3 years (-0.3% per year).
High Growth Earnings: OFSA3's earnings are forecast to decline over the next 3 years.
Revenue vs Market: OFSA3's revenue (5.8% per year) is forecast to grow slower than the BR market (7.7% per year).
High Growth Revenue: OFSA3's revenue (5.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: OFSA3's Return on Equity is forecast to be low in 3 years time (14.7%).
How has Ouro Fino Saúde Animal Participações performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OFSA3 has high quality earnings.
Growing Profit Margin: OFSA3's current net profit margins (14%) are higher than last year (7.9%).
Past Earnings Growth Analysis
Earnings Trend: OFSA3's earnings have grown significantly by 33.6% per year over the past 5 years.
Accelerating Growth: OFSA3's earnings growth over the past year (135.9%) exceeds its 5-year average (33.6% per year).
Earnings vs Industry: OFSA3 earnings growth over the past year (135.9%) exceeded the Pharmaceuticals industry 17.3%.
Return on Equity
High ROE: OFSA3's Return on Equity (19.7%) is considered low.
How is Ouro Fino Saúde Animal Participações's financial position?
Financial Position Analysis
Short Term Liabilities: OFSA3's short term assets (R$631.5M) exceed its short term liabilities (R$165.2M).
Long Term Liabilities: OFSA3's short term assets (R$631.5M) exceed its long term liabilities (R$294.8M).
Debt to Equity History and Analysis
Debt Level: OFSA3's debt to equity ratio (56.2%) is considered high.
Reducing Debt: OFSA3's debt to equity ratio has reduced from 62.1% to 56.2% over the past 5 years.
Debt Coverage: OFSA3's debt is well covered by operating cash flow (20.3%).
Interest Coverage: OFSA3's interest payments on its debt are well covered by EBIT (11.7x coverage).
What is Ouro Fino Saúde Animal Participações's current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OFSA3's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OFSA3's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OFSA3's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OFSA3's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: OFSA3 is not paying a notable dividend for the BR market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OFSA3's dividend in 3 years as they are not forecast to pay a notable one for the BR market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Kleber Cesar Gomes (46 yo)
Mr. Kleber Cesar Silveira Gomes serves as Chief Executive Officer at Ouro Fino Saúde Animal Participações S.A since April 1, 2020 and serves as its Member of Executive Board. Mr. Gomes served as Chief Inve...
Experienced Board: OFSA3's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Ouro Fino Saúde Animal Participações S.A.'s employee growth, exchange listings and data sources
- Name: Ouro Fino Saúde Animal Participações S.A.
- Ticker: OFSA3
- Exchange: BOVESPA
- Founded: 1987
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: R$1.511b
- Shares outstanding: 53.95m
- Website: https://www.ourofinosaudeanimal.com
Number of Employees
- Ouro Fino Saúde Animal Participações S.A.
- Rodovia Anhanguera SP 330
- Km 298
- São Paulo
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/26 22:57|
|End of Day Share Price||2021/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.